{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:19Z","timestamp":1794047479156,"version":"4.8.0"},"reference-count":78,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Recent updates have detailed how patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) may be better risk stratified using prognostic scoring systems. Most patients with NLPHL present with early-stage disease and have an indolent disease course. To reflect these differences from classic Hodgkin lymphoma, nomenclature has been updated to recognize nodular lymphocyte-predominant B-cell lymphoma as an alternative to NLPHL. The Global NLPHL One Working Group have published their pivotal dataset in 2024 which challenges the prognostic significance of variant immunoarchitectural (IAP) patterns and proposes a new prognostic scoring system. Key identified prognostic factors include age &gt;45 years, stage III-IV disease, hemoglobin &lt;10.5 g\/dL and splenic involvement. After multivariate analysis, variant IAP was not shown to be associated with inferior outcome. As most patients with NLPHL have excellent long-term survival, identifying patients where treatment de-escalation is appropriate will help to minimize toxicity. De-escalation strategies include observation after fully resected stage I disease, active surveillance, anti-CD20 antibody monotherapy, radiotherapy in early-stage disease, and avoiding anthracycline- or bleomycin-containing chemotherapy regimens. Evidence supporting the use of novel therapies remains limited with disappointing results from a recently published study of ibrutinib in patients with relapsed NLPHL. Hopefully, future trials will investigate novel agents such as checkpoint inhibitors, T-cell engaging antibodies and chimeric antigen receptor T-cell therapy.<\/jats:p>","DOI":"10.3324\/haematol.2024.285903","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:40:35Z","timestamp":1725550835000},"page":"3476-3487","source":"Crossref","is-referenced-by-count":13,"title":["Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment"],"prefix":"10.3324","volume":"109","author":[{"given":"Ross T.","family":"Salvaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Allanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"67879","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"67880","doi-asserted-by":"crossref","unstructured":"Binkley MS, Flerlage JE, Savage KJ. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J Clin Oncol. 2024; 42(19):2271-2280.","DOI":"10.1200\/JCO.23.01655"},{"key":"67881","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"67882","unstructured":"IARC. WHO classification of tumours of haematopoietic and lymphoid tissues. 2017."},{"key":"67883","doi-asserted-by":"crossref","unstructured":"Juntikka T, Malila N, Ylostalo T, Merikivi M, Jyrkkio S. Epidemiology of classic and nodular lymphocyte predominant Hodgkin lymphoma in Finland in 1996-2015. Acta Oncol. 2020; 59(5):574-581.","DOI":"10.1080\/0284186X.2019.1711166"},{"key":"67884","doi-asserted-by":"crossref","unstructured":"Goel A, Fan W, Patel AA, Devabhaktuni M, Grossbard ML. Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment. Clin Lymphoma Myeloma Leuk. 2014; 14(4):261-270.","DOI":"10.1016\/j.clml.2014.01.006"},{"key":"67885","doi-asserted-by":"crossref","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107(1):265-276.","DOI":"10.1182\/blood-2005-06-2508"},{"key":"67886","doi-asserted-by":"crossref","unstructured":"Nunez-Garcia B, Rodriguez-Pertierra M, Sequero S. Longterm follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: a report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2021; 39(4):506-512.","DOI":"10.1002\/hon.2835"},{"key":"67887","doi-asserted-by":"crossref","unstructured":"Posthuma HLA, Zijlstra JM, Visser O, Lugtenburg PJ, Kersten MJ, Dinmohamed AG. Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016. Br J Haematol. 2020; 189(1):117-121.","DOI":"10.1111\/bjh.16290"},{"key":"67888","doi-asserted-by":"crossref","unstructured":"Saarinen S, Aavikko M, Aittomaki K. Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood. 2011; 118(3):493-498.","DOI":"10.1182\/blood-2011-03-341560"},{"key":"67889","doi-asserted-by":"crossref","unstructured":"Saarinen S, Pukkala E, Vahteristo P, Makinen MJ, Franssila K, Aaltonen LA. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2013; 31(7):938-943.","DOI":"10.1200\/JCO.2012.43.5958"},{"key":"67890","doi-asserted-by":"crossref","unstructured":"Lorenzi L, Tabellini G, Vermi W. Occurrence of nodular lymphocyte-predominant Hodgkin lymphoma in Hermansky-Pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. PLoS One. 2013; 8(11):e80131.","DOI":"10.1371\/journal.pone.0080131"},{"key":"67891","doi-asserted-by":"crossref","unstructured":"van den Berg A, Maggio E, Diepstra A, de Jong D, van Krieken J, Poppema S. Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma. Blood. 2002; 99(4):1492-1494.","DOI":"10.1182\/blood.V99.4.1492"},{"key":"67892","doi-asserted-by":"crossref","unstructured":"Thurner L, Hartmann S, Fadle N. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. Nat Commun. 2020; 11(1):2465.","DOI":"10.1038\/s41467-020-16375-6"},{"key":"67893","doi-asserted-by":"crossref","unstructured":"Diehl V, Sextro M, Franklin J. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease. J Clin Oncol. 1999; 17(3):776-783.","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"67894","doi-asserted-by":"crossref","unstructured":"Nogova L, Reineke T, Brillant C. Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008; 26(3):434-439.","DOI":"10.1200\/JCO.2007.11.8869"},{"key":"67895","doi-asserted-by":"crossref","unstructured":"Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest. 2005; 128(4):2893-2909.","DOI":"10.1378\/chest.128.4.2893"},{"key":"67896","doi-asserted-by":"crossref","unstructured":"Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003; 27(10):1346-1356.","DOI":"10.1097\/00000478-200310000-00007"},{"key":"67897","doi-asserted-by":"crossref","unstructured":"Hartmann S, Eichenauer DA, Plutschow A. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013; 122(26):4246-4252.","DOI":"10.1182\/blood-2013-07-515825"},{"key":"67898","doi-asserted-by":"crossref","unstructured":"Hartmann S, Soltani AS, Bankov K. Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2022; 199(3):382-391.","DOI":"10.1111\/bjh.18376"},{"key":"67899","doi-asserted-by":"crossref","unstructured":"Younes S, Subramanian A, Khan A, Zhao S, Binkley M, Natkunam Y. Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell \/ histiocyte-rich large B-cell lymphoma. Blood Cancer J. 2024; 14(1):92.","DOI":"10.1038\/s41408-024-01073-z"},{"key":"67900","doi-asserted-by":"crossref","unstructured":"Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007; 110(9):3387-3390.","DOI":"10.1182\/blood-2007-03-082511"},{"key":"67901","doi-asserted-by":"crossref","unstructured":"Brune V, Tiacci E, Pfeil I. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008; 205(10):2251-2268.","DOI":"10.1084\/jem.20080809"},{"key":"67902","doi-asserted-by":"crossref","unstructured":"Hartmann S, Doring C, Jakobus C. Nodular lymphocyte predominant Hodgkin lymphoma and T cell \/ histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?. PLoS One. 2013; 8(11):e78812.","DOI":"10.1371\/journal.pone.0078812"},{"key":"67903","doi-asserted-by":"crossref","unstructured":"Hartmann S, Doring C, Vucic E. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell \/ histiocyte rich large B cell lymphoma. Br J Haematol. 2015; 169(3):415-422.","DOI":"10.1111\/bjh.13310"},{"key":"67904","doi-asserted-by":"crossref","unstructured":"Steidl C, Telenius A, Shah SP. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010; 116(3):418-427.","DOI":"10.1182\/blood-2009-12-257345"},{"key":"67905","doi-asserted-by":"crossref","unstructured":"Paschold L, Willscher E, Bein J. Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica. 2021; 106(10):2654-2666.","DOI":"10.3324\/haematol.2021.278427"},{"key":"67906","doi-asserted-by":"crossref","unstructured":"Khoury JD, Jones D, Yared MA. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004; 28(4):489-495.","DOI":"10.1097\/00000478-200404000-00008"},{"key":"67907","unstructured":"Rauf MS, Khan ZA, Zahir MN. FDG-PET utilizing Deauville scoring is superior to conventional imaging for staging and response assessment in pediatric and adult patients with nodular lymphocyte predominant Hodgkin\u2019s lymphoma. Blood. 2017; 130(Suppl 1):1519."},{"key":"67908","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2020; 136(26):2987-2993.","DOI":"10.1182\/blood.2019004044"},{"key":"67909","doi-asserted-by":"crossref","unstructured":"Shivarov V, Ivanova M. Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. Br J Haematol. 2018; 182(5):727-730.","DOI":"10.1111\/bjh.14861"},{"key":"67910","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Plutschow A, Fuchs M. Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group. J Clin Oncol. 2020; 38(7):698-705.","DOI":"10.1200\/JCO.19.00986"},{"key":"67911","doi-asserted-by":"crossref","unstructured":"Binkley MS, Rauf MS, Milgrom SA. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020; 135(26):2365-2374.","DOI":"10.1182\/blood.2019003877"},{"key":"67912","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Plutschow A, Schroder L. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018; 132(14):1519-1525.","DOI":"10.1182\/blood-2018-02-836437"},{"key":"67913","doi-asserted-by":"crossref","unstructured":"Strati P, Cheng PTM, Steiner RE. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol. 2021; 192(3):560-567.","DOI":"10.1111\/bjh.17281"},{"key":"67914","unstructured":"Eichenauer DA, Basaran A, Buhnen I. Patients with histopathological growth patterns D\/E constitute a high-risk group in nodular lymphocyte-predominant Hodgkin lymphoma: results from a comprehensive GHSG analysis. 2023. Publisher Full Text|"},{"key":"67915","doi-asserted-by":"crossref","unstructured":"Shankar AG, Kirkwood AA, Hall GW, Hayward J, O\u2019Hare P, Ramsay AD. Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma - a review of clinical outcome based on the histological variants. Br J Haematol. 2015; 171(2):254-262.","DOI":"10.1111\/bjh.13540"},{"key":"67916","doi-asserted-by":"crossref","unstructured":"Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma. J Clin Oncol. 2010; 28(5):793-799.","DOI":"10.1200\/JCO.2009.24.9516"},{"key":"67917","doi-asserted-by":"crossref","unstructured":"Biasoli I, Stamatoullas A, Meignin V. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010; 116(3):631-639.","DOI":"10.1002\/cncr.24819"},{"key":"67918","doi-asserted-by":"crossref","unstructured":"Advani RH, Horning SJ, Hoppe RT. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014; 32(9):912-918.","DOI":"10.1200\/JCO.2013.53.2069"},{"key":"67919","doi-asserted-by":"crossref","unstructured":"Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019; 184(1):17-29.","DOI":"10.1111\/bjh.15616"},{"key":"67920","doi-asserted-by":"crossref","unstructured":"Lazarovici J, Dartigues P, Brice P. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. Haematologica. 2015; 100(12):1579-1586.","DOI":"10.3324\/haematol.2015.133025"},{"key":"67921","doi-asserted-by":"crossref","unstructured":"Borchmann S, Joffe E, Moskowitz CH. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019; 133(20):2121-2129.","DOI":"10.1182\/blood-2018-10-877761"},{"key":"67922","doi-asserted-by":"crossref","unstructured":"Cortese MJ, Wei W, Hill BT. Outcomes of active surveillance versus initial treatment for nodular lymphocyte predominant Hodgkin lymphoma: a National Cancer Database (NCDB) analysis of 2,480 patients. Blood. 2020; 136(Suppl 1):29-30.","DOI":"10.1182\/blood-2020-142828"},{"key":"67923","doi-asserted-by":"crossref","unstructured":"Rogness VM, Wei W, Cortese M, Hill BT. Impact of active surveillance at time of diagnosis on overall survival in nodular lymphocyte-predominant Hodgkin lymphoma: a National Cancer Database study. Leuk Res. 2023; 134:107402.","DOI":"10.1016\/j.leukres.2023.107402"},{"key":"67924","doi-asserted-by":"crossref","unstructured":"Chen RC, Chin MS, Ng AK. Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010; 28(1):136-141.","DOI":"10.1200\/JCO.2009.24.0945"},{"key":"67925","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Plutschow A, Fuchs M. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015; 33(26):2857-2862.","DOI":"10.1200\/JCO.2014.60.4363"},{"key":"67926","doi-asserted-by":"crossref","unstructured":"Pinnix CC, Milgrom SA, Cheah CY. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2019; 3(9):1356-1367.","DOI":"10.1182\/bloodadvances.2018029140"},{"key":"67927","doi-asserted-by":"crossref","unstructured":"Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011; 118(17):4585-4590.","DOI":"10.1182\/blood-2011-07-365932"},{"key":"67928","unstructured":"Hoppe RT, Advani R, Ambinder RF. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Hodgkin Lymphoma. 2023. Publisher Full Text|"},{"key":"67929","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Aleman BMP, Andre M. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv19-iv29.","DOI":"10.1093\/annonc\/mdy080"},{"key":"67930","doi-asserted-by":"crossref","unstructured":"Wirth A, Yuen K, Barton M. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005; 104(6):1221-1229.","DOI":"10.1002\/cncr.21303"},{"key":"67931","doi-asserted-by":"crossref","unstructured":"Schulz H, Rehwald U, Morschhauser F. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: longterm results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008; 111(1):109-111.","DOI":"10.1182\/blood-2007-03-078725"},{"key":"67932","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Plutschow A, Fuchs M. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. Leukemia. 2020; 34(3):953-956.","DOI":"10.1038\/s41375-019-0609-3"},{"key":"67933","doi-asserted-by":"crossref","unstructured":"Gotti M, Sciarra R, Pulsoni A. Role of rituximab addition to first-line chemotherapy regimens in nodular lymphocyte-predominant Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. Hemasphere. 2023; 7(4):e837.","DOI":"10.1097\/HS9.0000000000000837"},{"key":"67934","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Buhnen I, Baues C. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies. Blood. 2023; 142(6):553-560.","DOI":"10.1182\/blood.2023019939"},{"key":"67935","doi-asserted-by":"crossref","unstructured":"Cheng PTM, Villa D, Tonseth RP. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Adv. 2021; 5(18):3647-3655.","DOI":"10.1182\/bloodadvances.2021004375"},{"key":"67936","doi-asserted-by":"crossref","unstructured":"Johnson P, Federico M, Kirkwood A. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016; 374(25):2419-2429.","DOI":"10.1056\/NEJMoa1510093"},{"key":"67937","doi-asserted-by":"crossref","unstructured":"Garciaz S, Harel S, Amorim S, Bouabdallah R, Thieblemont C, Brice P. Rituximab-ABV(D) for patients with nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. Br J Haematol. 2016; 175(4):735-737.","DOI":"10.1111\/bjh.13879"},{"key":"67938","doi-asserted-by":"crossref","unstructured":"Gloghini A, Bosco A, Ponzoni M, Spina M, Carbone A. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. Expert Rev Hematol. 2015; 8(2):217-223.","DOI":"10.1586\/17474086.2015.991388"},{"key":"67939","doi-asserted-by":"crossref","unstructured":"Hartmann S, Plutschow A, Mottok A. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol. 2019; 94(11):1208-1213.","DOI":"10.1002\/ajh.25607"},{"key":"67940","doi-asserted-by":"crossref","unstructured":"Fanale MA, Cheah CY, Rich A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017; 130(4):472-477.","DOI":"10.1182\/blood-2017-02-766121"},{"key":"67941","doi-asserted-by":"crossref","unstructured":"Xing KH, Connors JM, Lai A. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014; 123(23):3567-3573.","DOI":"10.1182\/blood-2013-12-541078"},{"key":"67942","doi-asserted-by":"crossref","unstructured":"Prusila REI, Haapasaari KM, Marin K. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. Acta Oncol. 2018; 57(9):1265-1267.","DOI":"10.1080\/0284186X.2018.1450522"},{"key":"67943","doi-asserted-by":"crossref","unstructured":"Vuolio T, Kuittinen O, Vayrynen JP. R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-an extended follow-up. Br J Haematol. 2023; 202(4):e24-e26.","DOI":"10.1111\/bjh.18896"},{"key":"67944","doi-asserted-by":"crossref","unstructured":"Wilson MR, Bagguley T, Smith A. Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study. Br J Haematol. 2019; 186(6):e214-e217.","DOI":"10.1111\/bjh.16109"},{"key":"67945","doi-asserted-by":"crossref","unstructured":"Shankar A, Hall GW, Gorde-Grosjean S. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin\u2019s lymphoma - an Anglo-French collaborative report. Eur J Cancer. 2012; 48(11):1700-1706.","DOI":"10.1016\/j.ejca.2011.10.018"},{"key":"67946","doi-asserted-by":"crossref","unstructured":"Akhtar S, Montoto S, Boumendil A. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation-Lymphoma Working Party. Am J Hematol. 2018; 93(1):40-46.","DOI":"10.1002\/ajh.24927"},{"key":"67947","doi-asserted-by":"crossref","unstructured":"Feugier P, Labouyrie E, Djeridane M. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood. 2004; 104(9):2675-2681.","DOI":"10.1182\/blood-2004-02-0567"},{"key":"67948","doi-asserted-by":"crossref","unstructured":"Eyre TA, Gatter K, Collins GP, Hall GW, Watson C, Hatton CS. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. Am J Hematol. 2015; 90(6):E103-110.","DOI":"10.1002\/ajh.23989"},{"key":"67949","doi-asserted-by":"crossref","unstructured":"Maco M, Kupcova K, Herman V. Circulating tumor DNA in Hodgkin lymphoma. Ann Hematol. 2022; 101(11):2393-2403.","DOI":"10.1007\/s00277-022-04949-x"},{"key":"67950","doi-asserted-by":"crossref","unstructured":"Calabretta E, di Trani M, Corrado F. Baseline circulating tumour DNA and interim PET predict response in relapsed \/ refractory classical Hodgkin lymphoma. Br J Haematol. 2023; 204(2):514-524.","DOI":"10.1111\/bjh.19162"},{"key":"67951","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Buhnen I, Plutschow A. Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Hematol Oncol. 2022; 40(4):801-804.","DOI":"10.1002\/hon.2986"},{"key":"67952","doi-asserted-by":"crossref","unstructured":"Ali SS, George R. Experience and outcome of patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) over 8 years. Blood. 2018; 132(Suppl 1):5352.","DOI":"10.1182\/blood-2018-99-119613"},{"key":"67953","doi-asserted-by":"crossref","unstructured":"Boll B, Borchmann P, Topp MS. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010; 148(3):480-482.","DOI":"10.1111\/j.1365-2141.2009.07963.x"},{"key":"67954","doi-asserted-by":"crossref","unstructured":"Cheah CY, Mistry HE, Konoplev S, Fowler NH. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma. 2016; 57(8):1974-1976.","DOI":"10.3109\/10428194.2015.1124993"},{"key":"67955","doi-asserted-by":"crossref","unstructured":"Siricilla M, Irwin L, Ferber A. A case of chemotherapy-refractory \u201cTHRLBCL like transformation of NLPHL\u201d successfully treated with lenalidomide. Case Rep Oncol Med. 2018; 2018:6137454.","DOI":"10.1155\/2018\/6137454"},{"key":"67956","doi-asserted-by":"crossref","unstructured":"Bein J, Thurner L, Hansmann ML, Hartmann S. Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse. Am J Hematol. 2020; 95(12):1495-1502.","DOI":"10.1002\/ajh.25972"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285903\/77629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285903\/77694","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11749\/77484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:15Z","timestamp":1794046035000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285903","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}